{"prompt": "['10.7.', 'Adverse Event Definition', '38', '10.7.1.', 'Pharmaceutical Product', '38', '10.7.2.', 'Medical Device', '38', '10.8.', 'Definition of Serious Adverse Event', '39', '10.9.', 'Follow-up Information on a Serious Adverse Event', '40', '10.10.', 'Abnormal Test Findings', '40', '10.11.', 'Relationship to Study Treatment', '41', '10.12.', 'Pregnancy', '42', '10.13.', 'Monitoring and Recording of Adverse Events', '42', '10.14.', 'Reporting of Serious Adverse Events', '43', '10.15.', 'Sponsor Responsibility for Expedited Safety Reports', '43', '11.', 'PLANNED STATISTICAL METHODS FOR ASSESSMENT OF', 'EFFICACY AND SAFETY', '45', '11.1.', 'General Considerations', '45', '11.2.', 'Analysis Populations', '45', '11.2.1.', 'Safety Population', '45', '11.2.2.', 'Modified Intent-to-Treat (MITT) Population', '45', '11.3.', 'Primary Efficacy Endpoint', '45', '11.3.1.', 'Secondary Efficacy Endpoint', '45', '11.4.', 'Tertiary Endpoints', '45', '11.5.', 'Exploratory Endpoints', '46', '11.5.1.', 'Week 1', '46', '11.5.2.', 'Week 6', '46', '11.5.3.', 'Week 12', '46', '11.6.', 'Determination of Sample Size', '46', '11.7.', 'Analysis of Primary Efficacy Endpoint', '46', '11.8.', 'Analysis of Other Efficacy Endpoints', '47', '11.9.', 'Analysis of the Safety Endpoints', '47', '11.10.', 'Protocol Deviations/Violations', '48', '12.', 'ETHICS AND GENERAL CLINICAL TRIAL CONDUCT', 'CONSIDERATIONS', '49', '12.1.', 'Institutional Review Board or Ethics Committee Approval', '49', '12.2.', 'Informed Consent', '49', 'Page 7 of 101']['12.3.', 'Patient Confidentiality', '50', '12.4.', 'Data Monitoring Committee(s)', '50', '13.', 'REGULATORY/ADMINISTRATIVE PROCEDURES AND', 'DOCUMENTATION', '51', '13.1.', 'Quality Control and Quality Assurance', '51', '13.2.', 'Investigators and Study Administrative Structure', '51', '13.3.', 'Study Monitoring', '51', '13.4.', 'Data Collection and Electronic Case Report Forms', '52', '13.5.', 'Access to Source Documentation', '52', '13.6.', 'Study Documentation and Retention of Records', '52', '14.', 'DISCLOSURE OF DATA AND PUBLICATION', '53', '15.', 'REFERENCES', '54', 'APPENDIX A. ASSESSMENT OF EFFICACY AND SAFETY', '56', 'APPENDIX B. CLINICAL SUPPLIES', '58', 'APPENDIX C. VICARES - PROTOCOL CL-001 CLINICAL STUDY', 'PROCEDURE MANUAL VERSION 1.1', '60', 'Page 8 of 101']['LIST OF TABLES', 'Table 1:', 'Study Endpoints', '21', 'Table 2:', 'Study Periods', '23', 'Table 3:', 'Visit Schedule and Assessments', '30', 'Table 4:', 'Adverse Event Causality Guidelines', '41', 'Table 5:', 'Description of Selected Scales for Efficacy Assessment', '56', 'Table 6:', 'Clinical Supplies', '59', 'LIST OF FIGURES', 'Figure 1: Study Design', '22', 'Page 9 of 101']\n\n###\n\n", "completion": "END"}